Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 223 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Adding Pembrolizumab to Standard Chemotherapy, Followed by Pembrolizumab Maintenance, Results in... March 30, 2023 Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says June 2, 2020 Taking pride in all of our researchers November 18, 2021 Opinion: ‘Wales needs more than a three-page statement to get cancer... March 22, 2021 Load more HOT NEWS Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis EMA Recommends Granting a Marketing Authorisation for Enfortumab Vedotin for the... FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for HER2-Mutated NSCLC Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based...
